EdisonTV

4SC

EdisonTV | Pharmaceutical & healthcare | 10/08/2017

Executive interview - 4SC

4SC is a Munich-based cancer biopharmaceutical company. In this interview Jason Loveridge, CEO of 4SC, provides an overview of the company, its recent equity capital raise (€41m gross) and its updated and progressive development plan.

4SC has initiated (late 2016) its pivotal 150-patient study with its lead candidate resminostat (HDAC inhibitor) for cutaneous T-cell lymphoma (CTCL). Top-line data are expected by 2019. Alongside resminostat, 4SC intends to advance 4SC-202 into a first pivotal study (late 2018) and complete formal development of 4SC-208 with the aim of starting Phase I/II clinical testing (early 2019). Alongside its main goal of executing accelerated routes to market for its core cancer products, it also achieves value by out-licensing non-core assets. For example, a partnership with Link Health in China for its oncology Eg5 inhibitor, 4SC-205 and a worldwide license for 4SC’s preclinical inhibitors of the Kv1.3 ion channel.

VolitionRx announces second quarter 2017 financial results

VolitionRx announces second quarter 2017 financial results

Cameron Reynolds, president and CEO of VolitionRx explains: “We have had numerous highlights this quarter, with strong progress being made on many fronts. I am delighted with the growing strength of new talent in our team, especially the growth in our Research & Development team in Belgium. We are also fortunate to be working with institutions and individuals who have brilliant reputations. We continue to announce large trials, such as the recent signing of a 13,500-patient US trial in colorectal cancer. We believe that this most recently announced trial, with a cost to us of only $3m, represents an exceptional value for our money. We look forward to achieving additional milestones in the upcoming quarters and sharing further exciting news.”
Watch »

10/08/2017 | VolitionRx

Executive interview - 4SC

Executive interview - 4SC

4SC is a Munich-based cancer biopharmaceutical company. In this interview Jason Loveridge, CEO of 4SC, provides an overview of the company, its recent equity capital raise (€41m gross) and its updated and progressive development plan.
Watch »

10/08/2017 | 4SC

Executive interview - e-Therapeutics

Executive interview - e-Therapeutics

e-Therapeutics (ETX) is a UK-based drug discovery company that has developed a proprietary, computer-based discovery platform based on network biology. In this interview Dr Ray Barlow, CEO of e-Therapeutics, provides an overview of the company, and outlines the output of its recent strategic review and its focus moving forward.
Watch »

09/08/2017 | e-Therapeutics

Executive interview - Volition Rx

Executive interview - Volition Rx

Volition America, a wholly owned subsidiary of VolitionRx Limited, announces a major new colorectal cancer screening trial with 13,500 patients. In collaboration with the Great Lakes New England Clinical Validation Center and funded by the US National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), this clinical study will seek to validate a panel of biomarkers that include Volition’s Nu.Q Colorectal Cancer Screening test in a large asymptomatic population to support US regulatory approval.
Watch »

18/07/2017 | VolitionRx

Executive Interview - Carmat

Executive Interview - Carmat

Stéphane Piat, CEO of Carmat, discusses the limitations of human heart transplant availability that build the commercial case for the development of its biocompatible artificial heart implant. He also outlines the characteristics that differentiate the Carmat heart from the SynCardia artificial heart and from ventricular assistance devices, which can potentially lead to better tolerability, less thrombosis risk and improved patient outcomes. He then discusses the next steps needed to advance the Carmat heart project and summarises the company’s financial position and requirements.
Watch »

26/06/2017 | Carmat

Executive Interview - Oryzon

Executive Interview - Oryzon

Carlos Buesa, CEO of Oryzon Genomics, discusses the company’s background and its ambition to lead the development of epigenetic therapeutics. Epigenetics is a relatively young field in terms of drug development and Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic drugs. Mr Buesa discusses how Oryzon developed expertise in epigenetics, describes its core technology platform and introduces its main products: ORY-1001, ORY-2001 and ORY-3001. The lead product, ORY-1001, is a first-in-class inhibitor of lysine specific demethylase 1 partnered with Roche, which took over further development after Oryzon delivered positive data from the Phase I/IIa in acute leukaemia in December 2016. Roche has also initiated a Phase I trial with ORY-1001 in small cell lung cancer. Oryzon’s second product, ORY-2001, targets Alzheimer’s disease and reported positive Phase I data in early April. Preclinical data also support its use in multiple sclerosis and other neurodegenerative indications. ORY-3001 has been recently revealed as the third product to enter pre-clinical development in non-oncological indications. Finally, Mr Buesa talks about main newsflow items expected from Oryzon over the next 24-36 months.
Watch »

02/05/2017 | Oryzon Genomics

Executive Interview - VolitionRx

Executive Interview - VolitionRx

VolitionRx (VNRX) is an international life sciences company developing simple, easy-to-use, blood-based cancer tests to accurately diagnose a range of cancers. In this interview, president and CEO Cameron Reynolds discusses last week’s earnings and looks forward to forthcoming milestones for 2017.
Watch »

14/03/2017 | VolitionRx

Executive interview - Imugene

Executive interview - Imugene

Imugene is a clinical-stage immuno-oncology company. Its lead product is HER-Vaxx, a B-cell peptide vaccine for the treatment of gastric cancer. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that overexpress the HER-2/neu receptor, such as breast cancer and gastric cancer. HER-Vaxx has successfully completed a Phase I study in breast cancer and has commenced a Phase Ib/II study in gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. Imugene has broadened its pipeline with the acquisition of arginine modulators (small molecules) to develop to preclinical proof of concept.
Watch »

09/03/2017 | Imugene

Executive interview - TiGenix

Executive interview - TiGenix

TiGenix is set for a decisive 2017 with possible EMA approval in H2 of the allogeneic stem cell therapy Cx601 to treat complex perianal fistulas in Crohn’s disease. This will trigger a €15m milestone from Takeda, the European partner; Takeda views Cx601 as a breakthrough therapy. A Phase I/II trial using stem cells to control severe sepsis, a major unmet need, has just started. Another interesting project is on acute cardiac stem cell therapy; Phase I/II data are expected in H117. The US IPO raised €31m net in 2016.
Watch »

07/03/2017 | TiGenix

Executive Interview - Touchstone Innovations

Executive Interview - Touchstone Innovations

Touchstone Innovations (previously Imperial Innovations) is an investment company focused on building and creating companies formed from scientific research in the ‘Golden Triangle’ (the geographical region encompassing London, Cambridge and Oxford). Touchstone has 107 companies in its portfolio, with 45 accelerated growth companies where the company actively invests or takes a seat on the board. The top 10 valued companies comprise 60.4% (£202.5m) of the total portfolio value (£335.1m as of 31 July 2016).
Watch »

05/01/2017 | Touchstone Innovations

News Announcement - VolitionRx

News Announcement - VolitionRx

Volition is a multi-national company developing simple, easy-to-use, blood-based cancer tests to accurately diagnose a range of cancers.
Watch »

03/01/2017 | VolitionRx

Executive Interview - ReNeuron

Executive Interview - ReNeuron

ReNeuron is a UK clinical-stage biotech company developing allogeneic cell-based therapies. CTX neural stem cells are in development for ischaemic stroke disability (Phase II) and critical limb ischaemia (Phase I), and human retinal progenitor cells (hRPC) are being studied for retinitis pigmentosa (Phase I/II). ReNeuron is one of the pioneers in the field of stem cells, having developed proprietary technology platforms, notably based on the CTX neural stem cell line, derived and immortalised from a single donor cell. It is developing these multipotent adult stem cells specifically for allogeneic administration (as opposed to autologous procedures). The final product can be cryopreserved, stored and transported, with a simple procedure to prepare the cells for injection, so offering a genuine off-the-shelf, cell-based therapy. There is a clear clinical and commercial appeal, in that rather than addressing the symptoms of a disease, stem cell therapy seeks to address the cause of the condition, to effect repair or reversal of the disease through the regeneration of the affected tissue.
Watch »

19/12/2016 | ReNeuron Group

Executive Interview - xBrane

Executive Interview - xBrane

Xbrane is a Swedish company focused on complex generics and biosimilars. Its leading products are Spherotide, a controlled release generic version of oncology drug Decapeptyl (sales of $0.5bn in 2015); and Xlucane, a biosimilar of Lucentis, which generated sales of $3.6bn in 2015. Xbrane has a specialised manufacturing facility for the production of Spherotide that involve a proprietary microsphere formulation. To manufacture Xlucane, the company utilises a proprietary strain of E. coli that yields 8 times more product and reduces costs by 85%. With low competition, Xbrane has a defined path to market through distribution agreements and partnering deals. The company has signed an agreement in Iran to start marketing its lead products in 2017. In China the company has recently signed an agreement for SEK87m (c $10m) to launch Spherotide in 2021. In the US and EU, Spherotide launch is expected in 2019. For Xlucane, Xbrane will conduct clinical development and registration activities during 2017-2019 with planned launch upon Lucentis patent expiration in 2020 in the US and 2022 in the EU.
Watch »

13/12/2016 | Xbrane Biopharma

Executive Interview - Abzena

Executive Interview - Abzena

Abzena (AIM:ABZA) is a UK life sciences group offering a range of services and technologies that enable its customers to develop safer and more effective biopharmaceutical products. Its core business is in its R&D service areas, which include immunology, protein engineering, ADC bioconjugation, synthetic chemistry and biomanufacturing.
Watch »

30/11/2016 | Abzena

Executive Interview - MISSION Therapeutics

Executive Interview - MISSION Therapeutics

MISSION Therapeutics, a Touchstone Innovations (AIM: IVO) investee company, is a Cambridge-based drug discovery company that is uniquely placed at the forefront of deubiquitylating enzyme (DUB) drug discovery and development. Since inception in 2011, MISSION has built and developed a proprietary chemistry platform and significant know-how in the generation of potent and selective small molecule DUB inhibitors. Ubiquitin is a small protein found in the vast majority of tissues and is involved in numerous cellular processes, including DNA damage and cell proliferation; DUBs are proteases that cleave ubiquitin from protein/other molecules. Hence targeting ubiquitin through the inhibition of DUBs holds the potential to generate novel drugs to treat cancer and other unmet medical needs, including neurodegenerative disease, inflammation, fibrosis, muscle wasting and infectious disease.
Watch »

24/11/2016 | MISSION Therapeutics

Executive Interview - NetScientific

Executive Interview - NetScientific

NetScientific is a healthcare investment company with a portfolio of digital health, diagnostic and therapeutic investees. In 2015 the company realigned its investment strategy, bringing a new highly experienced CEO on board and rationalising the portfolio and new funding (£18.2m gross from the issue of 15.2m new shares at 120p) to accelerate development in some of its key holdings. A series of value inflection points are expected in what remains of 2016 and 2017 including Series A financing for four holdings, the commercial ramp up of the Wanda digital health platform and the launch of the Vortex liquid biopsy product.
Watch »

08/11/2016 | NetScientific

Executive Interview - Crescendo

Executive Interview - Crescendo

Crescendo Biologics is a Cambridge-based, cancer-focused drug discovery and development company with a proprietary transgenic VH mouse platform and rapid formatting capabilities that are used to create its therapeutic product candidates, Humabodies. Humabodies are built from fully human single-domain antibody VH fragments (heavy chain variable domain) generated by a proprietary triple knockout transgenic mouse (Crescendo mouse) and can be bispecific or multi-specific. Its initial focus is on the development of Humabody drug conjugates (HDCs) and multi-specific checkpoint modulators.
Watch »

18/10/2016 | Crescendo

Executive Interview - PsiOxus

Executive Interview - PsiOxus

PsiOxus Therapeutics is an Oxford-based immunotherapy company that has developed a tumour-targeted delivery platform based on its lead oncolytic vaccine, Enadenotucirev (formerly ColoAd1). Enadenotucirev is an oncolytic virus that selectively kills cancer cells by lysis and is currently being studied in four clinical trials in various cancer indications. Under the PsiOxus collaboration with Bristol Myers Squibb, a Phase I combination study of Enadenotucirev with checkpoint inhibitor nivolumab (Opdivo) in a range of tumours, is due to start in Q316. PsiOxus also has a next-generation platform (T-SIGn Therapy) in development. This platform enables the anti-tumour effect of Enadenotucirev to be expanded through the addition of new genes (‘Armed EnAd’) creating a broad range of unique oncolytic immune therapeutics. NG-348, the first product candidate to emerge from this platform, will start Phase I in 2017.
Watch »

10/10/2016 | PsiOxus

EXTENDED Executive Interview with VolitionRX’s CEO Cameron Reynolds

EXTENDED Executive Interview with VolitionRX’s CEO Cameron Reynolds

VolitionRx (NASDAQ: VNRX), a life sciences company focused on developing diagnostic tests for cancer, announced on September 6th, that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition’s laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.
Watch »

08/09/2016 | VolitionRx

Executive Interview - VolitionRX

Executive Interview - VolitionRX

VolitionRx (NASDAQ: VNRX), a life sciences company focused on developing diagnostic tests for cancer, announced on September 6th, that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition’s laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.
Watch »

06/09/2016 | VolitionRx

Angle plc

Angle plc

Angle's proprietary Parsortix cell separation platform can be used to detect and harvest circulating tumour cells (CTCs) from blood. With its FY16 results released on 28 July, Angle delivered revenues of £361k, which represents a commercial milestone for the first ever sale of Parsortix for research use. Recently, Angle has announced results from two clinical studies carried out by its KOL partners. The initial data show that Parsortix performs as well as or better than current standard of care in detecting early-stage prostate cancer and assessing its severity and could potentially replace invasive tissue biopsy in metastatic breast cancer. Parsortix’s potential third application is for triaging women with ovarian masses before surgery, with clinical trials running in the US and Europe. In May, the company announced that the Cancer Research UK Manchester Institute is adopting Parsortix for routine research use, which will provide recurring sales. Angle raised £9.6m (net) in May, which adds safety margin to reach profitability, in our view.
Watch »

02/08/2016 | Angle